Mohammed Hadad -MD

⚖️💊 What happens when weight-loss drugs stop? The uncomfortable truth This 2026 BMJ systematic review and meta-analysis delivers one of the clearest reality checks yet on weight regain after stopping weight-management medications (WMMs), including GLP-1 and dual incretin therapies . 🔍 What was studied Across 37 studies (63 treatment arms, 9,341 adults) with overweight or obesity, the authors quantified how fast weight returns after discontinuing medication, and compared this with regain after behavioural weight-management programmes (BWMPs). Follow-up extended up to two years after treatment cessation. 📉 The headline finding On average, people regain 0.4 kg per month after stopping WMMs. At this pace, baseline weight is reached again within ~1.7 years. For newer, highly effective incretin drugs (e.g. semaglutide, tirzepatide), regain is even faster—up to 0.8 kg/month, with return to baseline in ~1.5 years. 🫀 Metabolic benefits fade too Improvements in HbA1c, fasting glucose, lipids, and blood pressure closely track weight. Once medication stops, cardiometabolic markers steadily worsen, returning to baseline within ~1.4 years. Weight loss without maintenance = temporary risk reduction. ⚠️ Worse than lifestyle alone When directly compared, weight regain after stopping drugs was significantly faster than after stopping behavioural programmes, independent of how much weight was initially lost. Bigger losses tended to rebound faster—biology pushes back hard. 🧠 Why this matters Obesity behaves like a chronic, relapsing disease. Short-term pharmacotherapy without a long-term plan risks disappointment, lost benefit, and misaligned expectations—for patients and health systems alike. 🔮 Bottom line Weight-loss drugs are powerful—but they don’t “cure” obesity. Their benefits persist only while treatment continues, or if embedded in a sustained, comprehensive strategy. Stopping therapy doesn’t just pause progress—it reverses it 🚨